Bitter pill
31 March 2021

The U.S. Federal Trade Commission wants to block Illumina’s $7.1 bln purchase of cancer-testing outfit Grail. Preventing the gene-sequencing group from reabsorbing a company it spun out in 2017 shows that watchdogs’ tougher thinking about competition is turning into action.